VaxPatch Advantage The company has developed VaxiPatch, a microneedle dermal patch platform, and has published early data on its use for influenza, signaling a potential scalable delivery technology that could be leveraged for additional vaccines and combination therapies.

COVID Vaccine Focus Active preclinical efforts on a COVID-19 vaccine using the VaxiPatch system indicate a readiness to engage in federal or large-scale vaccine programs and potential partnerships around novel delivery methods for pandemic preparedness.

Limited Resources With a small team (2-10 employees) and a private status, Verndari may seek co-development, contract manufacturing, or outsourcings with larger biotech firms or contract research organizations to scale development, testing, and regulatory activities.

Publications Momentum Recent publication in scientific journals about VaxiPatch for flu demonstrates validation and credibility that can be leveraged to attract grant funding, strategic partnerships, and investor interest in vaccine delivery tech.

Financial Signals Reported revenue in the low single to mid single digit millions suggests a need for additional capital or partnerships to accelerate clinical development and scale manufacturing for broader market opportunities.